Objective: Single cases and small series of Guillain-Barré syndrome (GBS) have been reported during the SARS-CoV-2 outbreak worldwide. We evaluated incidence and clinical features of GBS in a cohort of patients from two regions of northern Italy with the highest number of patients with COVID-19. Methods: GBS cases diagnosed in 12 referral hospitals from Lombardy and Veneto in March and April 2020 were retrospectively collected. As a control population, GBS diagnosed in March and April 2019 in the same hospitals were considered. Results: Incidence of GBS in March and April 2020 was 0.202/100 000/month (estimated rate 2.43/100 000/year) vs 0.077/100 000/month (estimated rate 0.93/100 000/year) in the same months of 2019 with a 2.6-fold increase. Estimated incidence of GBS in COVID-19-positive patients was 47.9/100 000 and in the COVID-19-positive hospitalised patients was 236/100 000. COVID-19-positive patients with GBS, when compared with COVID-19-negative subjects, showed lower MRC sum score (26.3±18.3 vs 41.4±14.8, p=0.006), higher frequency of demyelinating subtype (76.6% vs 35.3%, p=0.011), more frequent low blood pressure (50% vs 11.8%, p=0.017) and higher rate of admission to intensive care unit (66.6% vs 17.6%, p=0.002). Conclusions: This study shows an increased incidence of GBS during the COVID-19 outbreak in northern Italy, supporting a pathogenic link. COVID-19-associated GBS is predominantly demyelinating and seems to be more severe than non-COVID-19 GBS, although it is likely that in some patients the systemic impairment due to COVID-19 might have contributed to the severity of the whole clinical picture.

Filosto, M., Cotti Piccinelli, S., Gazzina, S., Foresti, C., Frigeni, B., Servalli, M. C., Sessa, M., Cosentino, G., Marchioni, E., Ravaglia, S., Briani, C., Castellani, F., Zara, G., Bianchi, F., Del Carro, U., Fazio, R., Filippi, M., Magni, E., Natalini, G., Palmerini, F., Perotti, A. M., Bellomo, A., Osio, M., Scopelliti, G., Carpo, M., Rasera, A., Squintani, G., Doneddu, P. E., Bertasi, V., Cotelli, M. S., Bertolasi, L., Fabrizi, G. M., Ferrari, S., Ranieri, F., Caprioli, F., Grappa, E., Broglio, L., De Maria, G., Leggio, U., Poli, L., Rasulo, F., Latronico, N., Nobile-Orazio, E., Padovani, A., Uncini, A., Guillain-Barré syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions, <<JOURNAL OF NEUROLOGY, NEUROSURGERY AND PSYCHIATRY>>, 2021; 92 (7): 751-756. [doi:10.1136/jnnp-2020-324837] [http://hdl.handle.net/10807/207223]

Guillain-Barré syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions

Magni, Eugenio;Natalini, Giuseppe;Caprioli, Francesca;De Maria, Giovanni;
2021

Abstract

Objective: Single cases and small series of Guillain-Barré syndrome (GBS) have been reported during the SARS-CoV-2 outbreak worldwide. We evaluated incidence and clinical features of GBS in a cohort of patients from two regions of northern Italy with the highest number of patients with COVID-19. Methods: GBS cases diagnosed in 12 referral hospitals from Lombardy and Veneto in March and April 2020 were retrospectively collected. As a control population, GBS diagnosed in March and April 2019 in the same hospitals were considered. Results: Incidence of GBS in March and April 2020 was 0.202/100 000/month (estimated rate 2.43/100 000/year) vs 0.077/100 000/month (estimated rate 0.93/100 000/year) in the same months of 2019 with a 2.6-fold increase. Estimated incidence of GBS in COVID-19-positive patients was 47.9/100 000 and in the COVID-19-positive hospitalised patients was 236/100 000. COVID-19-positive patients with GBS, when compared with COVID-19-negative subjects, showed lower MRC sum score (26.3±18.3 vs 41.4±14.8, p=0.006), higher frequency of demyelinating subtype (76.6% vs 35.3%, p=0.011), more frequent low blood pressure (50% vs 11.8%, p=0.017) and higher rate of admission to intensive care unit (66.6% vs 17.6%, p=0.002). Conclusions: This study shows an increased incidence of GBS during the COVID-19 outbreak in northern Italy, supporting a pathogenic link. COVID-19-associated GBS is predominantly demyelinating and seems to be more severe than non-COVID-19 GBS, although it is likely that in some patients the systemic impairment due to COVID-19 might have contributed to the severity of the whole clinical picture.
Inglese
Filosto, M., Cotti Piccinelli, S., Gazzina, S., Foresti, C., Frigeni, B., Servalli, M. C., Sessa, M., Cosentino, G., Marchioni, E., Ravaglia, S., Briani, C., Castellani, F., Zara, G., Bianchi, F., Del Carro, U., Fazio, R., Filippi, M., Magni, E., Natalini, G., Palmerini, F., Perotti, A. M., Bellomo, A., Osio, M., Scopelliti, G., Carpo, M., Rasera, A., Squintani, G., Doneddu, P. E., Bertasi, V., Cotelli, M. S., Bertolasi, L., Fabrizi, G. M., Ferrari, S., Ranieri, F., Caprioli, F., Grappa, E., Broglio, L., De Maria, G., Leggio, U., Poli, L., Rasulo, F., Latronico, N., Nobile-Orazio, E., Padovani, A., Uncini, A., Guillain-Barré syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions, <<JOURNAL OF NEUROLOGY, NEUROSURGERY AND PSYCHIATRY>>, 2021; 92 (7): 751-756. [doi:10.1136/jnnp-2020-324837] [http://hdl.handle.net/10807/207223]
File in questo prodotto:
File Dimensione Formato  
filosto et al, 2020.pdf

accesso aperto

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 536.73 kB
Formato Adobe PDF
536.73 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/207223
Citazioni
  • ???jsp.display-item.citation.pmc??? 78
  • Scopus 91
  • ???jsp.display-item.citation.isi??? 85
social impact